While Sonic Hedgehog (Shh) pathway inhibitors have shown promise in treating medulloblastomas exhibiting Shh pathway hyperactivity [1], these tumors comprise only a subset of medulloblastoma, and few consistent druggable targets have been described among Shh-independent variants of this tumor (e.g. Wnt subgroup, Group 3, and Group 4) [2]–[4]. This evidence concerns the gene SHH and medulloblastoma.